Alphamab Oncology (9966.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap8.46B
Enterprise Value8.33B
P/E Ratio-53.88
PEG Ratio0.33
Price/Sales Ratio9.98
Price/Book Ratio3.25
Enterprise/Revenue9.74
Enterprise/EBITDA-62.18

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterDecember 31, 2025

Profitability

Profit Margin-0.2
Operating Margin-0.27
AD

Management Effectiveness

Return On Assets-0.05
Return On Equity-0.06

Income Statement

Revenue551.58M
Revenue/Share0.59
Gross Profit426.67M
EBITDA-86.31M
Net Income-110.99M
Diluted EPS-0.12

Balance Sheet

Total Cash1.35B
Total Cash/Share1.41
Total Debt123.03M
Total Debt/Equity0.07
Current Ratio5.67
Book Value Per Share1.78

Price History

52-Week Change-3.74
52-Week High15.75
52-Week Low6.01
Moving Average 50 Days9.28
Moving Average 200 Days10.07

Statistics

Average Volume2.04M
Shares Outstanding968.66M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD